Tesamorelin units calculator
Tesamorelin (Egrifta) comes in two current formulations with different vials, diluents and doses. Pick the one on the prescription to see the label dose as mL and U-100 units, or enter any vial for plain arithmetic. It never suggests a dose.
- Free, no login
- Math only, never a dose suggestion
- Arithmetic checked Oct 25, 2026
Tesamorelin units calculator
FDA approvedWant this on paper? The printable dose chart covers every common vial and water amount.
Print the chartEmail it to meWhere the numbers come from
Both presets reproduce the FDA prescribing information, and the two products differ in almost every number.
| Egrifta WR (revised March 2025) | Egrifta SV (revised February 2024) | |
|---|---|---|
| Vial | 11.6 mg | 2 mg |
| Mixed with | 1.3 mL bacteriostatic water | 0.5 mL sterile water |
| Concentration (label) | 8 mg/mL | 4 mg/mL |
| Daily dose | 1.28 mg (0.16 mL, 16 units) | 1.4 mg (0.35 mL, 35 units) |
| Doses per vial | 7, one a day | 1; the rest is discarded |
| After mixing | Room temperature, 20 to 25 °C; discard after 7 days; do not refrigerate or freeze | Inject immediately; do not refrigerate or freeze |
The prescriber sets the dose. The mixing steps and sources are on the tesamorelin dosage page.
Why does Egrifta WR not divide evenly?
Because the label states its own concentration. 11.6 mg in 1.3 mL is about 8.9 mg/mL by straight division, but the label says 8 mg/mL and builds the 0.16 mL dose on that figure. The calculator uses the label's number. Whatever is left in the vial after seven doses is not an extra dose: the label says to discard the vial seven days after mixing.
What does "the 16 mark" mean?
It is the same 0.16 mL. The kits supply their own syringes, and the Egrifta WR instructions refer to the 16 mark. Units here are a volume, so 16 units means 0.16 mL on any U-100 scale. The amount of drug in that volume depends on the product, which is why the labels forbid swapping one for the other: 16 units of Egrifta SV holds only 0.64 mg.
Where does tesamorelin go?
Both labels say under the skin of the abdomen, rotating to a different area each time and avoiding scar tissue, bruises and the navel. Rotation counts here: injection site reactions occurred in 25% of people on tesamorelin versus 14% on placebo in the first 26 weeks of the trials. Neither label names a time of day, and neither describes a dose increase, a maintenance step or a taper. The printable dose tracker has a daily layout for recording each injection and site.
More on tesamorelin
The tesamorelin overview covers what it is approved for and what the trials found,tesamorelin side effects gives the label percentages, and sermorelin vs tesamorelin compares it with its older cousin.